[Music] We've all been there. Head down, thumb flicking, scrolling endlessly. Time just evaporating from us.But even knowing how empty this feels, it's estimated that over 75% of college students today doomscroll every day. Doom scrolling, the act of endlessly consuming bad reels, news, and memes. A quick show of thumbs in the room.Who here has been guilty of doom scrolling recently, perhaps over the last week or so. Thumbs down if you haven't. It's interesting to see quite a lot of thumbs up in the room of ...

[Music] Three years ago, I faced a major challenge as a teacher. The pandemic had forced our school online and my ninth grade students that were typically active, engaged, and collaborative in lessons were suddenly passive and disengaged online. I would send them into breakout rooms to collaborate on learning activities.And why when I entered those breakout rooms, I was met by awkward silence. It was like my students had forgot how to connect with other human beings. I realized I needed to do something as a ...

[Music] Good afternoon everyone. I'm and you or you can call me Kira and I come from the Mongol ethnic group in the hotel. Today I want to share with you a story about how three languages Mongolia, Chinese and English have shaped my identity, my life and my worldview.Growing up, I never thought of language as merely true to for communication. For me, each language is a doorway to a different world, a unique way of thinking and a distinct way of being. These three languages does not only define my cultural e ...

[Music] Well, hi everyone. I am Pal. As you heard, I'm a 21-year-old Zu change maker.What I don't tell often is that I'm an introvert turn speaker. So, when I stand on the stage, I'm nervous. And yes, I'm also a content creator.Do we recognize what this is. Do we recognize this. Everyone in the room from the nods and the smiles.Yes, this is an hourglass and I know we've been talking about the hourglass through different experiences and conversations and examples throughout the day, but we will continue to d ...

Nvidia (NVDA 2.05%) remains one of the best artificial intelligence (AI) stocks on the market. But with the chipmaker now trading at a price-to-sales multiple of 26.4, many investors may wonder if shares have gotten too expensive to buy. Don't be fooled: Nvidia stock is still reasonably priced.Nvidia stock isn't as expensive as it seemsNvidia designs graphics processing units (GPUs) that provide the processing power required to support modern AI and machine-learning software. The company's gross margins are ...

Core Insights - Salarius Pharmaceuticals is advancing its Phase 1/2 clinical study of seclidemstat for myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) with updates expected later this year [1][2] - The company is progressing with its planned merger with Decoy Therapeutics, which is anticipated to create value through Decoy's innovative peptide conjugate therapeutics platform [2][3] Company Developments - Salarius' seclidemstat is a first-in-class, orally bioavailable LSD1 inhibitor being evaluated at MD Anderson Cancer Center [1][9] - The merger with Decoy Therapeutics is set to create a new entity named Decoy Therapeutics, with Decoy investors expected to own approximately 92.4% of the merged company [2][10] - The combined company will focus on developing peptide conjugate therapeutics for unmet medical needs in respiratory infectious diseases and gastroenterology oncology [3][8] Research Insights - Recent animal studies published highlight the importance of inhibiting LSD1 expression, supporting the potential of SP-2577 in cancer treatment [2][5] - The studies provide insights into the role of KDM1A in regulating neural stem cell fate and its implications in oral squamous cell carcinoma progression [5][6] Future Plans - Decoy Therapeutics plans to advance its lead asset, a pan-coronavirus antiviral, towards an Investigational New Drug (IND) application with the FDA within the next 12 months [6][7] - The ongoing clinical trial at MDACC is expected to report data on patients with MDS and CMML who have previously failed or relapsed after hypomethylating agent therapy [7][9]

Core Insights - Salarius Pharmaceuticals is advancing its Phase 1/2 clinical study of seclidemstat for myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) with updates expected later this year [1][2] - The company is progressing with its planned merger with Decoy Therapeutics, which is anticipated to create value through Decoy's innovative peptide conjugate therapeutics [2][3] Company Developments - Salarius' seclidemstat is a first-in-class, orally bioavailable LSD1 inhibitor being evaluated at MD Anderson Cancer Center [1][9] - The merger with Decoy Therapeutics is set to combine Salarius' drug candidates with Decoy's IMPACT™ platform, which focuses on developing therapeutics for respiratory viruses and cancer [3][10] - The combined company will be led by Decoy's executive team, including CEO Frederick "Rick" Pierce and CSO Barbara Hibner [4] Research Insights - Two recent animal studies highlight the importance of inhibiting LSD1 expression, supporting the potential of SP-2577 in cancer treatment [2][5] - The studies published in peer-reviewed journals provide insights into the role of KDM1A in regulating neural stem cells and oral squamous cell carcinoma progression [5] Future Plans - Decoy plans to advance its lead asset, a pan-coronavirus antiviral, towards an Investigational New Drug (IND) application with the FDA within the next 12 months [6] - The ongoing clinical trial at MDACC may yield data on MDS and CMML patients who have previously failed or relapsed after hypomethylating agent therapy [7]

Core Insights - The article highlights the emergence of AI products developed by Chinese teams, particularly focusing on Pokee AI, which has successfully raised $12 million in seed funding aimed at automating enterprise workflows [1][12]. Group 1: Company Overview - Pokee AI is led by Bill Zhu, a former head of the reinforcement learning group at Meta, and aims to automate online workflows for users by integrating AI functionalities into existing tools and services [1][11]. - The funding round was led by Point72 Ventures, with participation from Qualcomm, Samsung, and other notable investors, indicating strong market interest and confidence in the product [1][12]. Group 2: Product Features - Pokee AI integrates AI capabilities into various platforms such as Google Workspace, Meta platforms, LinkedIn, and more, allowing users to automate tasks without switching between different tools [2][3]. - The product targets three core scenarios: AI + Productivity, AI + Social Media, and AI + Research & Engineering, addressing common pain points in workflow automation [9]. Group 3: Technology and Approach - Unlike many AI agents that rely on large language models (LLMs), Pokee AI utilizes reinforcement learning (RL) to tackle the execution of complex tasks, which is seen as a significant advantage [6][11]. - The RL approach allows the AI to learn from interactions with the environment, improving its decision-making and execution capabilities, achieving over 97% accuracy in selecting from thousands of tools [11]. Group 4: Market Context - The article notes a growing trend among Chinese AI teams to create innovative solutions for enterprise-level automation, with other products also securing significant funding and market traction [12][15]. - The focus on automating repetitive tasks and enhancing productivity reflects a broader industry shift towards integrating AI into everyday business processes [8][12].

French lessons offered as ferry visitors surge https://t.co/LWTWtzlP97 ...

Core Viewpoint - Victory Square Technologies Inc. reported solid financial results for Q1 2025 and emphasized its strategic focus on the digital health and wellness sectors, identifying significant growth opportunities in a fragmented healthcare market [4][11]. Financial Highlights - Adjusted Revenue for Q1 2025 was $6.528 million, while GAAP Revenue stood at $4.540 million. The Cost of Goods Sold (COGS) was $3.036 million, resulting in a Gross Margin of $1.504 million. As of March 31, 2025, the company had Cash & Marketable Securities amounting to $9.698 million [7]. Business Focus Areas - The company aims to scale its holdings in the digital health sector, particularly through its flagship portfolio company, Hydreight Technologies, which provides a compliant platform for healthcare services across the U.S. [4][8]. - Insu Therapeutics is developing a patent-pending oral insulin tablet, with early trials showing promising results in insulin uptake [8][14]. - Pawsible Ventures is focused on pet wellness and telehealth, leveraging trends in human healthcare, with the global pet care market projected to reach $368 billion by 2030 [10][14]. Portfolio Management - Victory Square actively manages its portfolio, having sold certain AI fintech solutions for approximately $880,000 in equity consideration in Q1 2025. This follows a previous sale of BlockX for about $1.7 million in listed shares [11][15]. Industry Context - The U.S. healthcare spending exceeds $4.5 trillion annually and is projected to reach $7 trillion by 2031, highlighting the sector's fragmentation and potential for value creation [4]. - The global diabetes therapeutics market is expected to reach $118 billion by 2032, with over 500 million people currently living with diabetes [14]. Upcoming Events - Victory Square will host an Investor Webinar on July 17, 2025, to provide updates and address investor questions [12]. Leadership and Strategy - The leadership team at Insu Therapeutics includes experienced professionals from academia and the pharmaceutical industry, indicating a strong foundation for advancing its clinical milestones [14]. - The company’s business model focuses on buying, building, and investing in early-stage tech companies, with a commitment to supporting their growth for up to 48 months [17].